Discovery Biotech — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Discovery Biotech is a private, clinical-stage biotechnology company founded in 2018, headquartered in San Diego, USA. The company is developing a pipeline of small molecule drug candidates specifically designed to address the critical challenge of Cancer Treatment Resistance Therapy (CTRT). With an initial portfolio of four products resulting from 15 years of foundational research, the company operates as a pre-revenue entity advancing therapies through preclinical and clinical development. Its business model is centered on therapeutic development, aiming to deliver novel drug inventions ready for clinical trials.

Oncology

Technology Platform

A small molecule drug discovery and development platform focused on identifying and targeting the complex mechanisms behind cancer treatment resistance, built on 15 years of foundational research.

Opportunities

The global unmet need in overcoming cancer therapy resistance is massive, affecting a large proportion of oncology patients and representing a major driver of mortality.

Successfully developing an effective therapy could command premium pricing and be used broadly in combination with existing standard-of-care treatments across multiple cancer types.

Risk Factors

The primary risk is the high scientific and clinical failure rate inherent in oncology drug development, especially for a complex problem like treatment resistance.

The company is also pre-revenue and privately held, facing significant financial risk if it cannot secure ongoing funding to advance its pipeline through costly clinical trials.

Competitive Landscape

The field of oncology and cancer resistance is intensely competitive, involving large pharmaceutical companies and numerous well-funded biotech startups. Discovery Biotech's claim of having the 'only effective solutions' is an unproven assertion that will be challenged by a wide array of approaches, including next-generation targeted therapies, immunotherapies, and novel drug delivery mechanisms.

More companies in Small Molecule Drugs →More companies in United States →